GNPX – Genprex, Inc.
Genprex, Inc.GNPX
$0.72Name : Genprex, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,125,810.00
EPSttm : -10.69
Genprex, Inc.
$0.72
2.86%$0.02Float Short %
4.79
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.82
EPS Last/This Y
18.31
EPS This/Next Y
3
Price
0.72
Target Price
7.5
Analyst Recom
1
Performance Q
108.76
Relative Volume
0.02
Beta
-0.92
Ticker: GNPX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | GNPX | 0.87 | N/A | N/A | 0 |
| 2024-12-20 | GNPX | 0.9439 | N/A | N/A | 0 |
| 2024-12-23 | GNPX | 0.9351 | N/A | N/A | 0 |
| 2024-12-24 | GNPX | 0.93 | N/A | N/A | 0 |
| 2024-12-26 | GNPX | 0.905 | N/A | N/A | 0 |
| 2024-12-27 | GNPX | 0.8911 | N/A | N/A | 0 |
| 2024-12-30 | GNPX | 0.8753 | N/A | N/A | 0 |
| 2024-12-31 | GNPX | 0.8663 | N/A | N/A | 0 |
| 2025-01-02 | GNPX | 0.878 | N/A | N/A | 0 |
| 2025-01-03 | GNPX | 0.844 | N/A | N/A | 0 |
| 2025-01-06 | GNPX | 0.8766 | N/A | N/A | 0 |
| 2025-01-07 | GNPX | 0.8399 | N/A | N/A | 0 |
| 2025-01-08 | GNPX | 0.7892 | N/A | N/A | 0 |
| 2025-01-09 | GNPX | 0.7711 | N/A | N/A | 0 |
| 2025-01-10 | GNPX | 0.7825 | N/A | N/A | 0 |
| 2025-01-13 | GNPX | 0.7301 | N/A | N/A | 0 |
| 2025-01-14 | GNPX | 0.7207 | N/A | N/A | 0 |
| 2025-01-15 | GNPX | 0.6955 | N/A | N/A | 0 |
| 2025-01-16 | GNPX | 0.7076 | N/A | N/A | 0 |
| 2025-01-17 | GNPX | 0.729 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | GNPX | 0.90 | 98.2 | - | -4.25 |
| 2024-12-20 | GNPX | 0.93 | 98.2 | - | -4.25 |
| 2024-12-23 | GNPX | 0.93 | 98.2 | - | -4.25 |
| 2024-12-24 | GNPX | 0.93 | 98.2 | - | -4.25 |
| 2024-12-26 | GNPX | 0.89 | 98.2 | - | -4.25 |
| 2024-12-27 | GNPX | 0.89 | 98.2 | - | -4.25 |
| 2024-12-30 | GNPX | 0.85 | 98.2 | - | -4.25 |
| 2024-12-31 | GNPX | 0.86 | 98.2 | - | -4.25 |
| 2025-01-02 | GNPX | 0.90 | 98.2 | - | -4.25 |
| 2025-01-03 | GNPX | 0.84 | 98.2 | - | -4.25 |
| 2025-01-06 | GNPX | 0.88 | 98.2 | - | -4.25 |
| 2025-01-07 | GNPX | 0.86 | 98.2 | - | -4.25 |
| 2025-01-08 | GNPX | 0.77 | 98.2 | - | -4.25 |
| 2025-01-09 | GNPX | 0.77 | 98.2 | - | -4.25 |
| 2025-01-10 | GNPX | 0.78 | 98.2 | - | -4.25 |
| 2025-01-13 | GNPX | 0.73 | 98.2 | - | -4.25 |
| 2025-01-14 | GNPX | 0.74 | 98.2 | - | -4.25 |
| 2025-01-15 | GNPX | 0.70 | 98.2 | - | -4.25 |
| 2025-01-16 | GNPX | 0.71 | 98.2 | - | -4.25 |
| 2025-01-17 | GNPX | 0.72 | 98.2 | - | -4.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | GNPX | 0.00 | 28.94 | 5.24 |
| 2024-12-20 | GNPX | 0.00 | 28.94 | 5.24 |
| 2024-12-23 | GNPX | 0.00 | 28.94 | 5.24 |
| 2024-12-24 | GNPX | 0.00 | 28.94 | 5.24 |
| 2024-12-26 | GNPX | 0.00 | 28.94 | 7.67 |
| 2024-12-27 | GNPX | 0.00 | 28.94 | 7.67 |
| 2024-12-30 | GNPX | 0.00 | 28.94 | 7.67 |
| 2024-12-31 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-02 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-03 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-06 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-07 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-08 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-09 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-10 | GNPX | 0.00 | 28.94 | 7.67 |
| 2025-01-13 | GNPX | 0.00 | 28.71 | 4.79 |
| 2025-01-14 | GNPX | 0.00 | 28.71 | 4.79 |
| 2025-01-15 | GNPX | 0.00 | 28.71 | 4.79 |
| 2025-01-16 | GNPX | 0.00 | 28.71 | 4.79 |
| 2025-01-17 | GNPX | 0.00 | 28.71 | 4.79 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.23
Avg. EPS Est. Current Quarter
-0.39
Avg. EPS Est. Next Quarter
-0.41
Insider Transactions
Institutional Transactions
28.71
Beta
-0.92
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
5
Growth Score
20
Sentiment Score
1
Actual DrawDown %
99.8
Max Drawdown 5-Year %
-99.9
Target Price
7.5
P/E
Forward P/E
PEG
P/S
P/B
2.37
P/Free Cash Flow
EPS
-11.92
Average EPS Est. Cur. Y
-4.25
EPS Next Y. (Est.)
-1.25
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.02
Return on Equity vs Sector %
-1383.1
Return on Equity vs Industry %
-1370.5
EPS 1 7Days Diff
1.3
EPS 1 30Days Diff
1.3
EBIT Estimation
Genprex, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 21
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
stock quote shares GNPX – Genprex, Inc. Stock Price stock today
news today GNPX – Genprex, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GNPX – Genprex, Inc. yahoo finance google finance
stock history GNPX – Genprex, Inc. invest stock market
stock prices GNPX premarket after hours
ticker GNPX fair value insiders trading